OTC Watch

All stocks / DFPH

Starling Oncology, Inc. DFPH

Starling Oncology (DFPH): convertible notes mentioned in an 8-K in July 2026, 3 insider sales or sale notices in 90 days and the latest annual figures in plain language. Each fact links to its SEC filing.

Insider sellingEstimated floatCostly financing Pink LimitedTaiwan
Live quote on OTC Markets

Market listing

Full name
DFP HOLDINGS LIMITED
Market tier
OTC Pink Limited
Trading status
Active
Last trade
Dec 11
Source: Stockwatch, 2026-11-17

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Revenue
$502,729,000
Net loss
($60,606,000)
What it means

It spends more than it earns

Under strain

Customers paid it $502.7 million in the year. It lost $60.6 million. For every $1 that came in, about $1.12 went out.

The report says
Cash and cash equivalents
$33,565,000
Net cash used in operating activities
($24,587,000)
What it means

It has cash for a while

Steady

It had $33.6 million in the bank and used about $2 million a month. At that pace the money lasts about 16 months unless it borrows or sells more shares.

The report says
Total assets
$164,656,000
Total liabilities
$180,376,000
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $164.7 million. Its debts and unpaid bills add up to $180.4 million. That is about $1.10 owed for every $1 owned.

What this adds up to

2 of 3 checks show strain. It spends more than it earns. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Insider selling2026-11-06

Chernett Jorey reported selling 2,851,061 shares for about $11,375,733 (Form 4, 2026-11-06).

Rule: Form 4 or Form 144 sale in the last 90 days. Source record

Estimated float2026-11-03

Estimated float about 89,180,233 shares as of 2026-11-03: 101,991,024 outstanding minus 12,810,791 held by 13 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Insider selling2026-08-21

Hively Brad reported selling 298,853 shares for about $1,946,310 (Form 4, 2026-08-21).

Rule: Form 4 or Form 144 sale in the last 90 days. Source record

Insider selling2026-08-21

BRADFORD HIVELY filed notice of a proposed sale of 298,853 shares (Form 144, 2026-08-21).

Rule: Form 4 or Form 144 sale in the last 90 days. Source record

Costly financing2026-07-07

8-K filed 2026-07-07 mentions: convertible note.

Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record

Shares outstanding

Source: SEC filings
2025-12-31
98.9M
2026-03-05
98.8M
2026-03-31
100.0M
2026-04-30
100.0M
2026-06-30
100.5M
2026-07-30
101.9M
2026-09-30
102.0M
2026-11-03
102.0M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-13 25-NSE
2026-11-13 4/A
2026-11-13 SCHEDULE 13G/A
2026-11-12 8-KFORM 8-K
2026-11-12 4
2026-11-12 8-K/AFORM 8-K
2026-11-10 4OWNERSHIP DOCUMENT
2026-11-06 10-Q10-Q
2026-11-05 8-KFORM 8-K
2026-09-02 8-KFORM 8-K
2026-08-24 4
2026-08-21 144

Common questions about DFPH

Does DFPH file reports with the SEC?

Yes. Starling Oncology files with the SEC under company number 0001799191. The most recent filing we hold is a 25-NSE dated 2026-11-13.

Source record

How many DFPH shares are outstanding?

101,991,024 shares as of 2026-11-03, as reported to the SEC.

Source record

Has DFPH filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Have DFPH insiders sold shares recently?

3 insider sales or sale notices were filed in the last 90 days. Most recent: Chernett Jorey reported selling 2,851,061 shares for about $11,375,733 (Form 4, 2026-11-06).

Source record

Who runs Starling Oncology?

Officers named in its insider filings: Robert Ross Carter (Chief Financial Officer), Kristin England (Chief Administrative Officer) and Jeffrey Langsam (Chief Clinical Officer).

Source record

Is Starling Oncology making money?

Customers paid it $502.7 million in the year. It lost $60.6 million. For every $1 that came in, about $1.12 went out. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record